Biota Announces Proposed Public Offering
January 09 2014 - 4:01PM
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the
"Company") today announced its intention, subject to market and
other conditions, to commence a public offering of its common
stock. The Company intends to use the net proceeds from the
offering for working capital and general corporate purposes.
Guggenheim Securities, LLC is acting as sole book-running
manager of the offering. The offering is being made pursuant to a
shelf registration statement previously filed with the Securities
and Exchange Commission ("SEC") and declared effective on October
17, 2013. A preliminary prospectus supplement relating to the
offering has been filed with the SEC. The offering will be made
only by means of a prospectus supplement and the accompanying base
prospectus. When available, copies of the prospectus supplement and
the accompanying prospectus relating to these securities may be
obtained from Guggenheim Securities, LLC, 330 Madison Avenue, 8th
Floor, New York, NY 10017, Attention: Equity Syndicate Department,
by telephone at (212) 518-9349 or by email to
GSEquityProspectusDelivery@guggenheimpartners.com. Electronic
copies of the prospectus supplement and the accompanying prospectus
will also be available on the website of the SEC at
http://www.sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy shares of common stock of Biota,
nor shall there be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Biota
Biota Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the discovery and development of products to prevent and
treat serious and potentially life-threatening infectious diseases.
The Company currently has two Phase 2 clinical-stage product
candidates in development: laninamivir octanoate, a long-acting
neuraminidase inhibitor that the Company is developing for the
treatment of influenza A and B infections under an investigational
new drug application (IND) in the United States through a contract
with the U.S. Office of Biomedical Advanced Research and
Development Authority (BARDA) that is designed to provide up to
$231 million in financial support to complete its clinical
development; and vapendavir, a potent, oral broad spectrum capsid
inhibitor of enteroviruses, including human rhinovirus (HRV). In
addition to these clinical-stage programs, the Company has a
preclinical program focused on developing treatments for
respiratory syncytial virus (RSV). For additional information
about the Company, please visit www.biotapharma.com.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve known and unknown risks and uncertainties. All
statements, other than historical facts are forward-looking
statements. Various important factors could cause actual
results, performance, events or achievements to materially differ
from those expressed or implied by the forward-looking statements,
including risks relating to the completion of the public
offering, including the satisfaction of customary closing
conditions and the use of anticipated proceeds, and other
cautionary statements contained elsewhere in this press release and
in the Company's Annual Report on Form 10-K for the year ended June
30, 2013, as filed with the SEC on September 27, 2013, and in the
Company's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2013, as filed with the SEC on November 12, 2013.
There may be events in the future that the Company is unable to
predict, or over which it has no control, and the Company's
business, financial condition, results of operations and prospects
may change in the future. The Company may not update these
forward-looking statements more frequently than quarterly unless it
has an obligation under U.S. Federal securities laws to do so.
Biota® is a registered trademark of Biota Holdings Limited.
CONTACT: Russell H. Plumb
Chief Executive Officer
(678) 221-3351
r.plumb@biotapharma.com
Lee M. Stern
The Trout Group
(646) 378-2922
lstern@troutgroup.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024